• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

    5/22/25 5:30:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email

    MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

    New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest step in the delivery of Sanofi's science-driven, best-in-class workplace portfolio worldwide, notably an expansive corporate hub and R&D center in Cambridge, Massachusetts, which opened in 2022. The New Jersey opening - an investment of $130 million - further strengthens Sanofi's presence in the United States.

    Paul Hudson

    Chief Executive Officer

    "Sanofi is an intrinsic part of the healthcare ecosystem of the United States, where we pioneer advancements in our labs, produce medicines and vaccines that improve people's lives, and grow our talented workforce. Our people are our biggest asset and providing them with a cutting-edge workplace experience is key to help them thrive and do their best work. These flagship offices are designed to inspire creativity, collaboration and innovation — all in service of patients."

    Phil Murphy

    Governor, New Jersey

    "Sanofi's investment in this innovative Morristown facility represents a significant vote of confidence in New Jersey's thriving innovation economy. This facility will drive scientific advancement and economic growth in our state, and its sustainable design and local partnerships will be an asset to the community. We are proud to see Sanofi deepen its commitment to New Jersey as we work together to shape the future of healthcare innovation."

    The new offices bring together nearly 2,000 employees across disciplines in a new 260,000-square-foot facility that features flexible workspaces, digitally enabled smart design, and best-in-class amenities, including wellness rooms, a restaurant open to the public, and the largest outdoor terrace space in New Jersey. Employees enjoy light-filled workspaces that utilize natural materials, largely sourced locally, as well as tactile finishes with contributions from local artists.

    Natalie Bickford

    Executive Vice President, Chief People Officer

    "Morristown exemplifies Sanofi's long-term investment in creating an empowering and purposeful workplace experience. When you walk in the door, you immediately feel that it's a different kind of workplace - digitally enabled, fully accessible and functional, but also beautiful and designed to make people feel connected and inspired. We look forward to welcoming Sanofians and visitors from around the world to our newest site."

    Sanofi's Morristown offices will be US Green Building Council LEED® Gold Certified and compliant with WELL Gold Building standards, incorporating sophisticated design elements that align with Sanofi's commitment to protect people, the planet, and the community. Employees will benefit from sustainable features such as fully subsidized and easily accessible public transportation, including Wi-Fi-enabled shuttles, and electric vehicle chargers on site. The building is designed to use approximately 28% less energy and reduce greenhouse gas emissions by over 24% compared to standard office spaces, while reducing water use by 37% through efficient fixtures and thoughtful design.

    Sanofi helps expand healthcare access in Morristown and beyond in New Jersey

    As part of its commitment to the Morristown community, Sanofi announced a financial contribution to Zufall Health Center, a nonprofit community health center providing affordable, high-quality healthcare for people regardless of income, insurance, or other barriers. The contribution will be used to support core services and team-based care, including updating essential equipment.

    In addition to announcing its support for the Zufall Health Center, Sanofi's Morristown offices will take part in the work of the Meal Recovery Coalition, of which the company is a founding member. Sanofi and other major New Jersey corporations and agencies in the Coalition recover surplus meals from large cafeterias and help to distribute them to food-insecure residents across the state. These partnerships reflect Sanofi's dedication to addressing healthcare disparities and strengthening community resources where its employees live and work.

    To explore career opportunities at Sanofi, please visit https://jobs.sanofi.com/en.

    About Sanofi

    We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

    Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

    Media Relations

    Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]

    Evan Berland | +1 215 432 0234 | [email protected]  

    Timothy Gilbert | +1 516 521 2929 | [email protected]

    Investor Relations

    Thomas Kudsk Larsen |+44 7545 513 693 | [email protected]  

    Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]  

    Felix Lauscher | +1 908 612 7239 | [email protected]  

    Keita Browne | +1 781 249 1766 | [email protected]  

    Nathalie Pham | +33 7 85 93 30 17 | [email protected]  

    Tarik Elgoutni | +1 617 710 3587 | [email protected]  

    Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]  

    Yun Li | +33 6 84 00 90 72 | [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sanofi-opens-new-130-million-nj-offices-in-morristown-showcasing-innovative-modern-design-and-strengthening-us-presence-302462270.html

    SOURCE Sanofi

    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    SEC Filings

    See more
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      6/18/25 6:43:11 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      6/17/25 8:33:31 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      6/6/25 11:35:15 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

      4 - Sanofi (0001121404) (Reporting)

      8/2/21 8:34:24 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by Sanofi

      3 - Sanofi (0001121404) (Reporting)

      7/28/21 8:32:04 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

      TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

      6/9/25 10:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

      MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster. New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest step in the delivery of Sanofi's science-driven, best-in-class workplace portfolio worldwide, notably an expansive corporate hub and R&D center in Cambridge, Massachusetts, which opened in

      5/22/25 5:30:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care